FDA Drug Shortage Database
Flurazepam (Dalmane) shortage
The FDA Drug Shortage Database lists 2 of 6 flurazepam presentations as limited or unavailable (updated September 15, 2026); the first entry was posted on August 3, 2022. 4 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule IV
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 15mg capsule | 1 | 2 | 0 |
| 30mg capsule | 1 | 2 | 0 |
Which presentations are listed?
Limited or unavailable now (2)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01) | Rising Pharma Holdings, Inc. | Current posted August 3, 2022, updated September 1, 2026 | Unavailable; Regulatory delay |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01) | Rising Pharma Holdings, Inc. | Current posted August 3, 2022, updated September 1, 2026 | Unavailable; Regulatory delay |
Listed now, available (4)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30) | Chartwell Molecular Holdings LLC | Current posted August 3, 2022, updated September 15, 2026 | Available |
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90) | Chartwell Molecular Holdings LLC | Current posted August 3, 2022, updated September 15, 2026 | Available |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30) | Chartwell Molecular Holdings LLC | Current posted August 3, 2022, updated September 15, 2026 | Available |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90) | Chartwell Molecular Holdings LLC | Current posted August 3, 2022, updated September 15, 2026 | Available |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Temazepam | Insomnia | No current entry | 20 labelers | $0.0767 per capsule 15 mg capsule |
| Triazolam | Insomnia | No current entry | 7 labelers | $0.308 per tablet 0.25 mg tablet |
| Estazolam | Insomnia | No current entry | 3 labelers | $0.839 per tablet 2 mg tablet |
| Quazepam | Insomnia | No current entry | none listed | n/a |
| Zolpidem | Insomnia | No current entry | 39 labelers | $0.0344 per tablet 5 mg tablet |
| Eszopiclone | Insomnia | No current entry | 27 labelers | $0.0993 per tablet 1 mg tablet |
| Ramelteon | Insomnia | A presentation being discontinued | 27 labelers | $0.660 per tablet 8 mg tablet |
| Zaleplon | Insomnia | No current entry | 9 labelers | $0.141 per capsule 10 mg capsule |
| Suvorexant | Insomnia | No current entry | none listed | $15.21 per tablet 10 mg tablet |
| Daridorexant | Insomnia | No current entry | none listed | $16.70 per tablet 25 mg tablet |
| Lemborexant | Insomnia | No current entry | none listed | $11.57 per tablet 10 mg tablet |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage